{"organizations": [], "uuid": "6859e48aac4c918cfc6d73ce01e829b03b200ec7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mithra-analysis-across-a-range-of/brief-mithra-analysis-across-a-range-of-parameters-points-to-limited-hemostatic-impact-for-estelle-idUSFWN1QQ05U", "country": "US", "domain_rank": 408, "title": "BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.237, "site_type": "news", "published": "2018-03-08T14:41:00.000+02:00", "replies_count": 0, "uuid": "6859e48aac4c918cfc6d73ce01e829b03b200ec7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mithra-analysis-across-a-range-of/brief-mithra-analysis-across-a-range-of-parameters-points-to-limited-hemostatic-impact-for-estelle-idUSFWN1QQ05U", "ord_in_thread": 0, "title": "BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-mithra analysis across a range of parameters points to limited hemostatic impact for estelle", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "ited hemostatic", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLEÂ®,\n* RESULTS CORROBORATE EARLIER FINDINGS AND FURTHER DELINEATE UNIQUE SAFETY PROFILE OF ESTELLE Source text : bit.ly/2tpdKwd Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2tpdKwd"], "published": "2018-03-08T14:41:00.000+02:00", "crawled": "2018-03-09T14:47:02.029+02:00", "highlightTitle": ""}